OBJECTIVE: Synuclein-γ (SNCG) is a marker for adverse and aggressive disease in breast cancer. In previous study, we found SNCG mRNA to be overexpressed in uterine serous carcinoma compared to uterine endometrioid adenocarcinoma. The aim of this study is to explore the prognostic value of SNCG in patients with endometrial cancer. METHODS: 279 endometrial cancer patients were retrieved from the archives. The tissue paraffin blocks were stained for SNCG antibody and its expression was correlated with clinicopathological prognostic factors. RESULTS: There was a positive association between SNCG(+) immunoexpression and tumor grade, tumor stage, type II carcinomas, deep myometrial invasion and lymphovascular invasion. A correlation between SNCG(+) and adverse outcomes, such as shorter overall survival (OS) and disease free survival (DFS), was also detected. Following adjuvant therapy (radiation and chemotherapy or chemotherapy alone), we observed a difference in 5years DFS rate between SNCG(+) (41.6%) and SNCG(-) patients (59.5%). CONCLUSION: Overexpression of SNCG seemed to be a predictor biomarker for aggressive tumor behavior and adverse outcome in patients with endometrial cancer. Future exploration of SNCG as a potential therapeutic target for selected patients could be of interest.
OBJECTIVE: Synuclein-γ (SNCG) is a marker for adverse and aggressive disease in breast cancer. In previous study, we found SNCG mRNA to be overexpressed in uterine serous carcinoma compared to uterine endometrioid adenocarcinoma. The aim of this study is to explore the prognostic value of SNCG in patients with endometrial cancer. METHODS: 279 endometrial cancerpatients were retrieved from the archives. The tissue paraffin blocks were stained for SNCG antibody and its expression was correlated with clinicopathological prognostic factors. RESULTS: There was a positive association between SNCG(+) immunoexpression and tumor grade, tumor stage, type II carcinomas, deep myometrial invasion and lymphovascular invasion. A correlation between SNCG(+) and adverse outcomes, such as shorter overall survival (OS) and disease free survival (DFS), was also detected. Following adjuvant therapy (radiation and chemotherapy or chemotherapy alone), we observed a difference in 5years DFS rate between SNCG(+) (41.6%) and SNCG(-) patients (59.5%). CONCLUSION: Overexpression of SNCG seemed to be a predictor biomarker for aggressive tumor behavior and adverse outcome in patients with endometrial cancer. Future exploration of SNCG as a potential therapeutic target for selected patients could be of interest.
Authors: Irina G Surgucheva; Jeremy M Sivak; M Elizabeth Fini; Robert E Palazzo; Andrei P Surguchov Journal: Arch Biochem Biophys Date: 2003-02-01 Impact factor: 4.013
Authors: Zhongkui Li; Guido M Sclabas; Bailu Peng; Kenneth R Hess; James L Abbruzzese; Douglas B Evans; Paul J Chiao Journal: Cancer Date: 2004-07-01 Impact factor: 6.860
Authors: Jacqueline Morgan; Anna V Hoekstra; Eloise Chapman-Davis; Jennifer L Hardt; J Julie Kim; Barbara M Buttin Journal: Gynecol Oncol Date: 2009-05-24 Impact factor: 5.482
Authors: Abigail D Winder; Kruti P Maniar; Jian-Jun Wei; Dachao Liu; Denise M Scholtens; John R Lurain; Julian C Schink; Barbara M Buttin; Virginia L Filiaci; Heather A Lankes; Nilsa C Ramirez; Kay Park; Meenakshi Singh; Richard W Lieberman; Robert S Mannel; Matthew A Powell; Floor J Backes; Cara A Mathews; Michael L Pearl; Angeles Alvarez Secord; David J Peace; David G Mutch; William T Creasman; J Julie Kim Journal: Cancer Date: 2016-12-07 Impact factor: 6.860
Authors: Gustavo Ayala; Matteo Morello; Anna Frolov; Sungyong You; Rile Li; Fabiana Rosati; Gianluca Bartolucci; Giovanna Danza; Rosalyn M Adam; Timothy C Thompson; Michael P Lisanti; Michael R Freeman; Dolores Di Vizio Journal: J Pathol Date: 2013-07-08 Impact factor: 7.996
Authors: Anna Strohl; Kristina Mori; Stacey Akers; Wiam Bshara; Barbara Buttin; Peter J Frederick; Irene B Helenowski; Carl D Morrison; Kunle Odunsi; Julian C Schink; Denise M Scholtens; Jian-Jun Wei; J Julie Kim Journal: J Ovarian Res Date: 2016-11-03 Impact factor: 4.234
Authors: Kathrin Schaal; Marc Hirschfeld; Peter Bronsert; Hannah Füllgraf; Markus Jäger; Bettina Herde; Claudia Nöthling; Sebastian Mayer; Thalia Erbes; Elmar Stickeler Journal: Oncotarget Date: 2015-09-08
Authors: Noémi Csibi; Réka Brubel; Noémi Dobó; Katalin Viola Mészáros; Attila Molvarec; Péter Lukovich; János Rigó; Attila Z Bokor Journal: Med Sci Monit Date: 2020-05-12